Continental Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Continental Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-17,500	Closed	-$930K	–	132
2013 Q4	$930K	Sell	17,500 -12,500	-42%	-$637K	0.2%	105
2013 Q3	$1.39M	Hold	30,000	–	–	0.34%	79
2013 Q2	$1.34M	Buy	+30,000	New	+$1.3M	0.38%	75

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Continental Advisors's BMY Position: Q2 2026 in Review

Continental Advisors increased its Bristol-Myers Squibb (BMY) stake by 13% in Q2 2026, buying an estimated $517K and bringing the position to 78,754 shares worth $4.54M. The position accounts for 1.92% of the portfolio, ranked #21.

Continental Advisors first reported a position in BMY in Q2 2013 and has held it in 6 quarters since. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Continental Advisors held 78,754 shares of Bristol-Myers Squibb worth $4.54M as of Q2 2026.
Continental Advisors bought 9,000 Bristol-Myers Squibb shares in Q2 2026, an estimated $517K.
Bristol-Myers Squibb made up 1.92% of Continental Advisors's portfolio in Q2 2026, its #21 holding.
Continental Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 6 quarters since.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Continental Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.